DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition
出版年份 2023 全文链接
标题
DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 164, Issue -, Pages 106477
出版商
Elsevier BV
发表日期
2023-10-18
DOI
10.1016/j.biocel.2023.106477
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
- (2023) Natasja L. de Vries et al. NATURE
- Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
- (2023) Fangcen Liu et al. ONCOLOGIST
- Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
- (2023) Dung T. Le et al. EUROPEAN JOURNAL OF CANCER
- Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
- (2023) Peter M. K. Westcott et al. NATURE GENETICS
- Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
- (2023) Guillaume Mestrallet et al. Frontiers in Immunology
- Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
- (2022) Razvan Cristescu et al. Journal for ImmunoTherapy of Cancer
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
- (2021) Rajasekharan Somasundaram et al. Nature Communications
- Spatially organized multicellular immune hubs in human colorectal cancer
- (2021) Karin Pelka et al. CELL
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
- (2021) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
- (2021) Huabin Hu et al. Lancet Gastroenterology & Hepatology
- Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability‐high solid tumors
- (2020) Mohamed E. Salem et al. INTERNATIONAL JOURNAL OF CANCER
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- cGAS-STING signaling in cancer immunity and immunotherapy
- (2020) Huashan Du et al. BIOMEDICINE & PHARMACOTHERAPY
- DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
- (2020) Changzheng Lu et al. CANCER CELL
- MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway
- (2020) Junhong Guan et al. CANCER CELL
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Revisiting immune escape in colorectal cancer in the era of immunotherapy
- (2019) Marieke Erica Ijsselsteijn et al. BRITISH JOURNAL OF CANCER
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
- (2019) Birgit Geoerger et al. LANCET ONCOLOGY
- Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
- (2018) Na Luo et al. OncoImmunology
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Exploiting DNA mismatch repair deficiency as a therapeutic strategy
- (2014) Delphine Guillotin et al. EXPERIMENTAL CELL RESEARCH
- cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
- (2013) Andrea Ablasser et al. NATURE
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More